Fibrinolysis and the control of blood coagulation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Broos, 2011, Platelets at work in primary hemostasis, Blood Rev, 25, 155, 10.1016/j.blre.2011.03.002
de Witt, 2014, Insights into platelet-based control of coagulation, Thromb Res, 133, S139, 10.1016/S0049-3848(14)50024-2
Furie, 2009, Pathogenesis of thrombosis, Hematology Am Soc Hematol Educ Program, 255, 10.1182/asheducation-2009.1.255
Bagoly, 2012, Factor XIII, clot structure, thrombosis, Thromb Res, 129, 382, 10.1016/j.thromres.2011.11.040
Hajjar, 2014, The molecular basis of fibrinolysis
Wolberg, 2007, Thrombin generation and fibrin clot structure, Blood Rev, 21, 131, 10.1016/j.blre.2006.11.001
Aleman, 2014, Fibrinogen and red blood cells in venous thrombosis, Thromb Res, 133, S38, 10.1016/j.thromres.2014.03.017
Gersh, 2010, Flow rate and fibrin fiber alignment, J Thromb Haemost, 8, 2826, 10.1111/j.1538-7836.2010.04118.x
Campbell, 2010, Flow profoundly influences fibrin network structure: implications for fibrin formation and clot stability in haemostasis, Thromb Haemost, 104, 1281, 10.1160/TH10-07-0442
Neeves, 2010, Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow, Biophys J, 98, 1344, 10.1016/j.bpj.2009.12.4275
Blombäck, 1994, Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation, Thromb Res, 75, 521, 10.1016/0049-3848(94)90227-5
Wolberg, 2002, Analyzing fibrin clot structure using a microplate reader, Blood Coagul Fibrinolysis, 13, 533, 10.1097/00001721-200209000-00008
Wolberg, 2003, Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk, Blood, 101, 3008, 10.1182/blood-2002-08-2527
Undas, 2011, Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases, Arterioscler Thromb Vasc Biol, 31, e88, 10.1161/ATVBAHA.111.230631
Cilia La Corte, 2011, Role of fibrin structure in thrombosis and vascular disease, Adv Protein Chem Struct Biol, 83, 75, 10.1016/B978-0-12-381262-9.00003-3
Wolberg, 2005, High dose factor VIIa improves clot structure and stability in a model of haemophilia B, Br J Haematol, 131, 645, 10.1111/j.1365-2141.2005.05820.x
Gray, 2011, Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma, Thromb Res, 128, 570, 10.1016/j.thromres.2011.04.009
Cawthern, 1998, Blood coagulation in hemophilia A and hemophilia C, Blood, 91, 4581, 10.1182/blood.V91.12.4581
Carr, 1995, Effect of fibrin structure on plasmin-mediated dissolution of plasma clots, Blood Coagul Fibrinolysis, 6, 567, 10.1097/00001721-199509000-00011
Gabriel, 1992, The effect of fibrin structure on fibrinolysis, J Biol Chem, 267, 24259, 10.1016/S0021-9258(18)35759-4
Longstaff, 2011, The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies, Blood, 117, 661, 10.1182/blood-2010-06-290338
Collet, 2003, Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots, J Biol Chem, 278, 21331, 10.1074/jbc.M212734200
Cooper, 2003, Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure, Blood, 102, 535, 10.1182/blood-2002-10-3150
Mannila, 2007, Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors, J Thromb Haemost, 5, 766, 10.1111/j.1538-7836.2007.02406.x
Walton, 2014, The fibrinogen γA/γ′ isoform does not promote acute arterial thrombosis in mice, J Thromb Haemost, 12, 680, 10.1111/jth.12534
Rijken, 2009, New insights into the molecular mechanisms of the fibrinolytic system, J Thromb Haemost, 7, 4, 10.1111/j.1538-7836.2008.03220.x
Bu, 1994, Cellular receptors for the plasminogen activators, Blood, 83, 3427, 10.1182/blood.V83.12.3427.3427
Cesarman-Maus, 2005, Molecular mechanisms of fibrinolysis, Br J Haematol, 129, 307, 10.1111/j.1365-2141.2005.05444.x
Hoylaerts, 1982, Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin, J Biol Chem, 257, 2912, 10.1016/S0021-9258(19)81051-7
Tate, 1987, Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis, Biochemistry, 26, 338, 10.1021/bi00376a002
Travis, 1983, Human plasma proteinase inhibitors, Annu Rev Biochem, 52, 655, 10.1146/annurev.bi.52.070183.003255
Schneider, 2004, A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis, J Biol Chem, 279, 13333, 10.1074/jbc.M313164200
Coolman, 2006, Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy, Eur J Obstet Gynecol Reprod Biol, 128, 22, 10.1016/j.ejogrb.2006.02.004
Coolman, 2012, Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes, Obstet Gynecol, 119, 1190, 10.1097/AOG.0b013e318256187f
Broze, 1996, Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma, Blood, 88, 3815, 10.1182/blood.V88.10.3815.bloodjournal88103815
Mosnier, 2001, The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration, Thromb Haemost, 86, 1035, 10.1055/s-0037-1616530
Plow, 1981, The presence and release of alpha 2-antiplasmin from human platelets, Blood, 58, 1069, 10.1182/blood.V58.6.1069.1069
Ichinose, 1983, Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin, FEBS Lett, 153, 369, 10.1016/0014-5793(83)80645-0
Kimura, 1986, Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor, J Biol Chem, 261, 15591, 10.1016/S0021-9258(18)66755-9
Doolittle, 2008, Searching for differences between fibrinogen and fibrin that affect the initiation of fibrinolysis, Cardiovasc Hematol Agents Med Chem, 6, 181, 10.2174/187152508784871954
Thorsen, 1992, The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis, Ann N Y Acad Sci, 667, 52, 10.1111/j.1749-6632.1992.tb51597.x
Bai, 2011, The novel plasminogen receptor, plasminogen receptor(KT) (Plg-R(KT)), regulates catecholamine release, J Biol Chem, 286, 33125, 10.1074/jbc.M111.218693
Stahl, 1995, The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae, J Cell Biol, 129, 335, 10.1083/jcb.129.2.335
Okamoto, 1998, Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane, J Biol Chem, 273, 5419, 10.1074/jbc.273.10.5419
Rescher, 2008, S100A10/p11: family, friends and functions, Pflugers Arch, 455, 575, 10.1007/s00424-007-0313-4
Gerke, 2005, Annexins: linking Ca2+ signalling to membrane dynamics, Nat Rev Mol Cell Biol, 6, 449, 10.1038/nrm1661
Fatimathas, 2010, Annexins as disease modifiers, Histol Histopathol, 25, 527
Rescher, 2004, Annexins—unique membrane binding proteins with diverse functions, J Cell Sci, 117, 2631, 10.1242/jcs.01245
Hajjar, 1990, Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase, J Biol Chem, 265, 2908, 10.1016/S0021-9258(19)39887-4
Waisman, 1995, Annexin II, tetramer: structure and function, Mol Cell Biochem, 149–150, 301, 10.1007/BF01076592
Flood, 2011, The annexin A2 system and vascular homeostasis, Vascul Pharmacol, 54, 59, 10.1016/j.vph.2011.03.003
Cesarman-Maus, 2011, Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis, Stroke, 42, 501, 10.1161/STROKEAHA.110.592121
Cesarman-Maus, 2006, Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome, Blood, 107, 4375, 10.1182/blood-2005-07-2636
Sebastiani, 2005, Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia, Nat Genet, 37, 435, 10.1038/ng1533
Flanagan, 2011, Genetic predictors for stroke in children with sickle cell anemia, Blood, 117, 6681, 10.1182/blood-2011-01-332205
Menell, 1999, Annexin II and bleeding in acute promyelocytic leukemia, N Engl J Med, 340, 994, 10.1056/NEJM199904013401303
Stein, 2009, The coagulopathy of acute promyelocytic leukaemia revisited, Best Pract Res Clin Haematol, 22, 153, 10.1016/j.beha.2008.12.007
O'Connell, 2011, Regulation of S100A10 by the PML-RAR-α oncoprotein, Blood, 117, 4095, 10.1182/blood-2010-07-298851
Bailey, 1955, The clotting of fibrinogen. I. The liberation of peptide material, Biochim Biophys Acta, 18, 495, 10.1016/0006-3002(55)90140-2
Latallo, 1962, Inhibition of fibrin polymerization by fibrinogen proteolysis products, Am J Physiol, 202, 681, 10.1152/ajplegacy.1962.202.4.681
Khalafallah, 2014, Evaluation of the innovance d-dimer assay for the diagnosis of disseminated intravascular coagulopathy in different clinical settings, Clin Appl Thromb Hemost, 20, 91, 10.1177/1076029612454936
van der Hulle, 2013, Selective D-dimer testing for the diagnosis of acute deep vein thrombosis: a validation study, J Thromb Haemost, 11, 2184, 10.1111/jth.12419
van der Hulle, 2013, Variable D-dimer thresholds for diagnosis of clinically suspected acute pulmonary embolism, J Thromb Haemost, 11, 1986, 10.1111/jth.12394
Gomes, 2014, Risk assessment for thrombosis in cancer, Semin Thromb Hemost, 40, 319, 10.1055/s-0034-1370770
Jennewein, 2011, Novel aspects of fibrin(ogen) fragments during inflammation, Mol Med, 17, 568, 10.2119/molmed.2010.00146
Senior, 1986, Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B, J Clin Investig., 77, 1014, 10.1172/JCI112353
Richardson, 1976, Chemotaxis for human monocytes by fibrinogen-derived peptides, Br J Haematol, 32, 507, 10.1111/j.1365-2141.1976.tb00953.x
Lalla, 2003, Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells, Arch Oral Biol, 48, 263, 10.1016/S0003-9969(03)00005-0
Roesner, 2009, Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion, Crit Care Med, 37, 598, 10.1097/CCM.0b013e3181959a12
Gröger, 2009, Peptide Bbeta(15-42) preserves endothelial barrier function in shock, PLoS ONE, 4, e5391, 10.1371/journal.pone.0005391
Pandi, 2009, Two families of synthetic peptides that enhance fibrin turbidity and delay fibrinolysis by different mechanisms, Biochemistry, 48, 7201, 10.1021/bi900647g
Mischke, 2004, Detection of anticoagulant activities of isolated canine fibrinogen degradation products X, Y, D and E using resonance thrombography, Blood Coagul Fibrinolysis, 15, 81, 10.1097/00001721-200401000-00013
Mischke, 2000, Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma, Haemostasis, 30, 123
Ittyerah, 1979, Effect of fibrin degradation products and thrombin on fibrinogen synthesis, Br J Haematol, 43, 661, 10.1111/j.1365-2141.1979.tb03799.x
Omar, 1987, Inactivation of factor Va by plasmin, J Biol Chem, 262, 9750, 10.1016/S0021-9258(18)47998-7
McKee, 1975, Molecular structural studies of human factor VIII, Ann N Y Acad Sci, 240, 8, 10.1111/j.1749-6632.1975.tb53319.x
Esmon, 1987, The regulation of natural anticoagulant pathways, Science, 235, 1348, 10.1126/science.3029867
Stricker, 1986, Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation, Blood, 68, 275, 10.1182/blood.V68.1.275.275
Adelman, 1986, Proteolysis of platelet glycoprotein by plasmin is facilitated by plasmin lysine-binding regions, Blood, 68, 1280, 10.1182/blood.V68.6.1280.1280
Gimple, 1989, Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant issue type plasminogen activator, Circulation, 80, 581, 10.1161/01.CIR.80.3.581
Coller, 1990, Platelets and thrombolytic therapy, N Engl J Med, 322, 33, 10.1056/NEJM199001043220107
Esmon, 1989, The roles of protein C and thrombomodulin in the regulation of blood coagulation, J Biol Chem, 264, 4743, 10.1016/S0021-9258(18)83649-3
Grinnell, 1996, Surface thrombomodulin modulates thrombin receptor responses on vascular smooth muscle cells, Am J Physiol, 270, H603
Lafay, 1998, Thrombomodulin modulates the mitogenic response to thrombin of human umbilical vein endothelial cells, Thromb Haemost, 79, 848, 10.1055/s-0037-1615076
Bajzar, 1995, Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor, J Biol Chem, 270, 14477, 10.1074/jbc.270.24.14477
de Munk, 1991, Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin, J Clin Invest, 88, 1680, 10.1172/JCI115483
Molinari, 1992, Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator in vitro and in a perfused rabbit heart model, Thromb Haemost, 67, 226, 10.1055/s-0038-1648417
Preissner, 1997, Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling, Thromb Haemost, 78, 88, 10.1055/s-0038-1657507
Esmon, 2001, Anticoagulant protein C/thrombomodulin pathway, vol. 8th, 4327
de Moerloose, 2008, Treatment of congenital fibrinogen disorders, Expert Opin Biol Ther, 8, 979, 10.1517/14712598.8.7.979
Matsuda, 1999, Structure and function of fibrinogen: insights from dysfibrinogens, Thromb Haemost, 82, 283
Côté, 1998, gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen, Blood, 92, 2195, 10.1182/blood.V92.7.2195
Lijnen, 1984, Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation, Thromb Haemost, 51, 108, 10.1055/s-0038-1661033
Lak, 1999, Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia, Br J Haematol, 107, 204, 10.1046/j.1365-2141.1999.01681.x
Dupuy, 2003, Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha, J Thromb Haemost, 1, 1096, 10.1046/j.1538-7836.2003.00208.x
Manco-Johnson, 2009, Pharmacokinetics and safety of fibrinogen concentrate, J Thromb Haemost, 7, 2064, 10.1111/j.1538-7836.2009.03633.x
Bornikova, 2011, Fibrinogen replacement therapy for congenital fibrinogen deficiency, J Thromb Haemost, 9, 1687, 10.1111/j.1538-7836.2011.04424.x
Chapin, 2013, Pulmonary embolism in a patient with congenital afibrinogenemia, Haemophilia, 19, e380, 10.1111/hae.12234
Hunt, 2014, Bleeding and coagulopathies in critical care, N Engl J Med, 370, 2153
Tripodi, 2011, The coagulopathy of chronic liver disease, N Engl J Med, 365, 147, 10.1056/NEJMra1011170
Malyszko, 2002, Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome, Blood Coagul Fibrinolysis, 13, 615, 10.1097/00001721-200210000-00006
Cucuianu, 1991, Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states, Thromb Haemost, 66, 586, 10.1055/s-0038-1646464
Sallah, 2000, Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel, Cancer Investig, 18, 191, 10.3109/07357900009031823
Meikle, 1967, Fibrinolysis and hemorrhage in a fatal case of heat stroke, N Engl J Med, 276, 911, 10.1056/NEJM196704202761607
Bouchama, 1996, Activation of coagulation and fibrinolysis in heatstroke, Thromb Haemost, 76, 909, 10.1055/s-0038-1650685
Hess, 2008, The coagulopathy of trauma: a review of mechanisms, J Trauma, 65, 748, 10.1097/TA.0b013e3181877a9c
Edmunds, 2010, Managing fibrinolysis without aprotinin, Ann Thorac Surg, 89, 324, 10.1016/j.athoracsur.2009.10.043
Krone, 2010, Impaired fibrinolysis in the antiphospholipid syndrome, Curr Rheumatol Rep, 12, 53, 10.1007/s11926-009-0075-4
Arteel, 2008, New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury, J Gastroenterol Hepatol, 23, S54, 10.1111/j.1440-1746.2007.05285.x
Mazur, 2014, Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications, Thromb Res, 134, 510, 10.1016/j.thromres.2014.05.041
van Marion, 2005, Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis, Thromb Haemost, 94, 1341, 10.1055/s-0037-1615590
Deng, 2006, Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator, Arch Dermatol, 142, 1466, 10.1001/archderm.142.11.1466
Pizzo, 1986, Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator, Arch Pathol Lab Med, 110, 517
Tefs, 2006, Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients, Blood, 108, 3021, 10.1182/blood-2006-04-017350
Miyauchi, 1996, Operative treatment of intramedullary hematoma associated with congenital deficiency of alpha 2-plasmin inhibitor: a report of three cases, J Bone Joint Surg Am, 78, 1409, 10.2106/00004623-199609000-00019
Carpenter, 2008, Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance, Haemophilia, 14, 1250, 10.1111/j.1365-2516.2008.01766.x
Iwaki, 2012, PAI-1, progress in understanding the clinical problem and its aetiology, Br J Haematol, 157, 291, 10.1111/j.1365-2141.2012.09074.x
Iwaki, 2012, The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human, Thromb Res, 129, e161, 10.1016/j.thromres.2011.10.008
Mehta, 2008, Plasminogen activator inhibitor type 1 deficiency, Haemophilia, 14, 1255, 10.1111/j.1365-2516.2008.01834.x
Carmeliet, 1994, Physiological consequences of loss of plasminogen activator gene function in mice, Nature, 368, 419, 10.1038/368419a0
Karamanavi, 2014, Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice, Transl Oncol, 7, 10.1016/j.tranon.2014.02.002
Hugenholtz, 2013, TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation, Thromb Haemost, 109, 948, 10.1160/TH12-12-0930
Ridker, 1992, Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor, Circulation, 85, 1822, 10.1161/01.CIR.85.5.1822
Crowther, 2001, Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study, Thromb Haemost, 85, 390, 10.1055/s-0037-1615594
Folsom, 2003, Prospective study of fibrinolytic markers and venous thromboembolism, J Clin Epidemiol, 56, 598, 10.1016/S0895-4356(03)00052-0
van Tilburg, 2000, Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis, Blood, 95, 2855, 10.1182/blood.V95.9.2855.009k02_2855_2859
Lisman, 2005, Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis, Blood, 105, 1102, 10.1182/blood-2004-08-3253
Meltzer, 2008, Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis, PLoS Med, 5, e97, 10.1371/journal.pmed.0050097
Hoekstra, 2010, Impaired fibrinolysis as a risk factor for Budd–Chiari syndrome, Blood, 115, 388, 10.1182/blood-2009-03-211557
Meltzer, 2009, Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men, Br J Haematol, 145, 121, 10.1111/j.1365-2141.2008.07569.x
Meltzer, 2010, Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1, Blood, 116, 113, 10.1182/blood-2010-02-267740
Meltzer, 2009, Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men, Haematologica, 94, 811, 10.3324/haematol.2008.002386
De Wee, 2012, Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease, Haemophilia, 18, 444, 10.1111/j.1365-2516.2011.02645.x
Rijken, 2012, Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests, J Thromb Haemost, 10, 2116, 10.1111/j.1538-7836.2012.04901.x
Sivula, 2009, Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation, Blood Coagul Fibrinolysis, 20, 419, 10.1097/MBC.0b013e32832a76e1
Ogawa, 2012, A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery, Transfusion, 52, 14, 10.1111/j.1537-2995.2011.03241.x
Brazzel, 2013, Thromboelastography-guided transfusion. Therapy in the trauma patient, AANA J, 81, 127
Schöchl, 2011, FIBTEM provides early prediction of massive transfusion in trauma, Crit Care, 15, R265, 10.1186/cc10539
Huissoud, 2009, Coagulation assessment by rotation thrombelastometry in normal pregnancy, Thromb Haemost, 101, 755, 10.1160/TH08-06-0386
Schöchl, 2009, Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry, J Trauma, 67, 125, 10.1097/TA.0b013e31818b2483
Popa, 2014, Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling, J Bone Miner Metab, 32, 124, 10.1007/s00774-013-0475-4
Dougherty, 1999, The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival, Proc Natl Acad Sci U S A, 96, 686, 10.1073/pnas.96.2.686
Ling, 2004, Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo, J Clin Invest, 113, 38, 10.1172/JCI19684
Nikolopoulos, 2014, The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis, Clin Chem Lab Med, 52, 937, 10.1515/cclm-2013-1124
Tsantes, 2007, Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis, Blood Coagul Fibrinolysis, 18, 497, 10.1097/MBC.0b013e3281ec4eee
Tsantes, 2008, The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk, Thromb Res, 122, 736, 10.1016/j.thromres.2007.09.005
Jannes, 2004, Tissue plasminogen activator −7351C/T enhancer polymorphism is a risk factor for lacunar stroke, Stroke, 35, 1090, 10.1161/01.STR.0000124123.76658.6c
Shi, 2014, Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis, Thromb Res, 134, 610, 10.1016/j.thromres.2014.06.023
Verdú, 2008, Association between the Thr325Ile and Ala147Thr polymorphisms of the TAFI gene and the risk of venous thromboembolic disease, Clin Appl Thromb Hemost, 14, 494, 10.1177/1076029607309185
Tàssies, 2009, Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome, Thromb Res, 124, 614, 10.1016/j.thromres.2009.07.004
Bugge, 1995, Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction, Genes Dev, 9, 794, 10.1101/gad.9.7.794
Ploplis, 1995, Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice, Circulation, 92, 2585, 10.1161/01.CIR.92.9.2585
Lijnen, 1999, Alpha2-Antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding, Blood, 93, 2274, 10.1182/blood.V93.7.2274
Carmeliet, 1993, Plasminogen activator inhibitor-1 gene-deficient mice: I. Generation by homologous recombination and characterization, J Clin Invest, 92, 2746, 10.1172/JCI116892
Nagashima, 2002, Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life, J Clin Invest, 109, 110